SU Khan, M Singh, S Valavoor, MU Khan, AN Lone… - Circulation, 2020 - Am Heart Assoc
Background: The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention with drug-eluting stents remains uncertain. We compared short-term (< …
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
H Watanabe, T Domei, T Morimoto, M Natsuaki… - Jama, 2019 - jamanetwork.com
Importance Very short mandatory dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with a drug-eluting stent may be an attractive option. Objective …
Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y 12 inhibitor prevents ischaemic events after coronary stenting, but increases bleeding. Guidelines support …
EP Navarese, F Andreotti, V Schulze, M Kołodziejczak… - bmj, 2015 - bmj.com
Objective To assess the benefits and risks of short term (< 12 months) or extended (> 12 months) dual antiplatelet therapy (DAPT) versus standard 12 month therapy, following …
S Degrauwe, T Pilgrim, A Aminian, S Noble… - Open …, 2017 - openheart.bmj.com
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in …
S Cassese, RA Byrne, T Tada, LA King… - European heart …, 2012 - academic.oup.com
Aims The aim of this study was to evaluate benefits and risks of extending dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in the drug-eluting stent era …